(0.01%) 5 479.00 points
(-0.01%) 38 814 points
(0.05%) 19 932 points
(0.26%) $80.54
(1.04%) $2.82
(0.12%) $2 331.90
(-0.33%) $29.30
(-0.03%) $970.60
(0.04%) $0.932
(-0.09%) $10.64
(0.09%) $0.788
(-1.87%) $86.80
2 days till quarter result
(bmo 2024-06-20)
Expected move: +/- 11.20%
Live Chart Being Loaded With Signals
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom...
Stats | |
---|---|
Šios dienos apimtis | 539 096 |
Vidutinė apimtis | 1.11M |
Rinkos kapitalizacija | 469.28M |
EPS | $-0.550 ( Q1 | 2024-03-31 ) |
Kita pelno data | ( $-0.420 ) 2024-06-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-4.98 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0180 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-03 | Guyer David R | Buy | 3 250 | Common Stock |
2024-06-03 | Guyer David R | Sell | 6 525 | Stock Option (Right to Buy) |
2024-06-03 | Guyer David R | Buy | 6 525 | Common Stock |
2024-06-03 | Guyer David R | Sell | 3 250 | Stock Option (Right to Buy) |
2024-06-03 | Guyer David R | Sell | 11 625 | Common Stock |
INSIDER POWER |
---|
62.49 |
Last 98 transactions |
Buy: 1 910 587 | Sell: 476 799 |
Tūris Koreliacija
EyePoint Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
WDAY | 0.904 |
WRAP | 0.894 |
GTEC | 0.884 |
CTSH | 0.878 |
DOMO | 0.87 |
JBHT | 0.867 |
HURN | 0.864 |
ZS | 0.861 |
APLS | 0.86 |
DRUG | 0.859 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
TNDM | -0.893 |
VIRT | -0.886 |
PUI | -0.884 |
MMLP | -0.881 |
TIGO | -0.86 |
HCM | -0.854 |
RILYG | -0.854 |
BNTC | -0.854 |
BILI | -0.854 |
VERU | -0.852 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
EyePoint Pharmaceuticals Koreliacija - Valiuta/Žaliavos
EyePoint Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $46.02M |
Bruto pelnas: | $41.39M (89.93 %) |
EPS: | $-1.820 |
FY | 2023 |
Pajamos: | $46.02M |
Bruto pelnas: | $41.39M (89.93 %) |
EPS: | $-1.820 |
FY | 2022 |
Pajamos: | $41.40M |
Bruto pelnas: | $33.08M (79.89 %) |
EPS: | $-3.34 |
FY | 2021 |
Pajamos: | $36.94M |
Bruto pelnas: | $28.76M (77.86 %) |
EPS: | $-4.55 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.